Skip to main content

Table 4 Treatment-related adverse events

From: Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial

 

Any grade

Grade 3

Grade 4

Hematologic

 Neutropenia

23 (71.9)

6 (18.8)

7 (21.9)

 Anemia

7 (21.9)

1 (3.1)

0

 Thrombopenia

5 (15.6)

2 (6.3)

0

 Febrile Neutropenia

1 (3.1)

1 (3.1)

0

Nonhematologic

 Fatigue

16 (50.0)

4 (12.5)

0

 Alopecia

22 (68.7)

N/A

 Peripheral neuropathy

15 (46.9)

4 (12.5)

0

 Arthralgia

4 (12.6)

0

0

 Constipation

7 (21.9)

1 (3.1)

0

 Diarrhea

2 (6.2)

0

0

 Nausea

8 (25.0)

0

0

 Vomitting

1 (3.1)

0

0

 Stomatitis

9 (28.1)

2 (6.3)

0